Greg Roumeliotis, MSc, Orgenesis, Germantown, MD, provides an overview of major issues currently facing decentralized manufacturing, such as developing collaborative environments to foster innovation, as well as manufacturing accessible and affordable therapies of clinical quality. He additionally describes how Orgenesis Mobile Production Units and Labs (OMPULs) have enabled the point-of-care development of cell and gene therapies on a large-scale and the production of advanced therapies close to treatment centers and hospitals in various countries around the world. This interview took place at Advanced Therapies Week 2022.